A new 14-valent pneumococcal conjugate vaccine (PNEUBEVAX 14™) developed by Biological E demonstrates safety and immunogenicity in Phase 3 trial with infant participants.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.